BioCryst halts en­roll­ment in all stud­ies for its lead pipeline can­di­date — shares crash

BioCryst is tak­ing a beat­ing Fri­day morn­ing af­ter re­port­ing it would pause en­roll­ment in three stud­ies for its lead pipeline pro­gram.

In a terse …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA